congresses-banner

The content contained is subject

PublicationView

Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Breast Cancer
A health-related quality of life (QOL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) versus capecitabine (CAP) in patients with hormone receptor–positive (HR+), HER2-low metastatic breast cancer (mBC)
Naoto Ueno
Oral
Dato-DXd
ESMO Breast 2024 | May 15-17, 2024
Breast Cancer
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in pretreated, inoperable/metastatic HR+/HER2– breast cancer: Additional safety analysis from TROPION-Breast01
Komal Jhaveri
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Breast Cancer
Exploratory pooled safety analysis of trastuzumab deruxtecan (T-DXd) in patients with HER2+ or HER2-low unresectable and/or metastatic breast cancer in DESTINY-Breast trials
Yeon Hee Park
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Breast Cancer
French real-world safety and effectiveness of trastuzumab deruxtecan (T-DXd) in the treatment of patients with HER2+ metastatic or unresectable breast cancer (m/u BC): First results of REALITY-01 ambispective study
Jean-Yves Pierga
Mini-Oral
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Other/Multi-Tumor
Pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment after recovery from grade 1 interstitial lung disease/pneumonitis (ILD)
Hope S. Rugo
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Breast Cancer
PROVIDENCE: A prospective, non-interventional study examining real-world clinical and patient-reported outcome (PRO) data in patients (pts) with HER2-positive or HER2-low unresectable or metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
Manfred Welslau
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Breast Cancer
Real-world treatment patterns in patients with HER2 positive unresectable or metastatic breast cancer: HER2 REAL study final analysis in Asia-Pacific (APAC) and Brazil
Carlos Barrios
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Breast Cancer
Safety, tolerability, and antitumor activity of T-DXd in patients with HER2-positive mBC and active brain metastases in DESTINY-Breast07
Carey Anders
Mini-Oral
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Breast Cancer
Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2+ metastatic breast cancer previously treated with trastuzumab emtansine: Updated overall survival results of the randomized, phase 3 DESTINY-Breast02 study
Sung-Bae Kim
Poster
Dato-DXd
ESMO Breast 2024 | May 15-17, 2024
Breast Cancer
TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd) + durvalumab followed by adjuvant durvalumab vs standard of care in treatment-naïve early-stage triple negative and HR-low/HER2– breast cancer
Sibylle Loibl
Pages: 1  2  

footer